Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on July 3, 2003

Stroke. 2003
Published online before print July 3, 2003, doi: 10.1161/01.STR.0000080941.73934.30
A more recent version of this article appeared on August 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/8/2019    most recent
01.STR.0000080941.73934.30v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niessen, F.
Right arrow Articles by Hossmann, K.-A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niessen, F.
Right arrow Articles by Hossmann, K.-A.
Related Collections
Right arrow Animal models of human disease
Right arrow Thrombin
Right arrow Embolic stroke
Right arrow Intracerebral Hemorrhage
Right arrow Thrombolysis

Submitted on April 4, 2003
Accepted on April 10, 2003

Differences in Clot Preparation Determine Outcome of Recombinant Tissue Plasminogen Activator Treatment in Experimental Thromboembolic Stroke

Frank Niessen MD; Thomas Hilger PhD; Mathias Hoehn PhD; and Konstantin-A. Hossmann MD, PhD*

From the Department of Experimental Neurology, Max-Planck-Institute for Neurological Research, Cologne, Germany.

* To whom correspondence should be addressed. E-mail: hossmann{at}mpin-koeln.mpg.de.

Background and Purpose--Thrombin-induced clots used in experimental thromboembolic stroke differ from clots forming spontaneously under clinical conditions. We investigated whether this difference influences the efficacy and outcome of thrombolytic treatment.

Methods--In rats, the middle cerebral artery was occluded by intracarotid injection of fibrin-rich clots, prepared either according to established methods by adding thrombin to freshly drawn arterial blood or by spontaneous coagulation. The mechanical properties of clots were determined in vitro by elasticity and plasticity tests. One hour after embolism, thrombolysis was started by intra-arterial application of recombinant tissue plasminogen activator (rtPA) (10 mg/kg). Treatment efficacy was monitored by MR measurements of blood perfusion, apparent diffusion coefficient (ADC), T2 relaxation time and blood-brain barrier permeability, and by pictorial measurements of ATP and pH.

Results--Thrombin-induced clots were classified as elastic, and spontaneously forming clots were classified as plastic. Middle cerebral artery embolism with thrombin-induced or spontaneously forming clots led to similar reduction of perfusion and ADC, but rtPA treatment efficacy differed greatly. In the spontaneously forming clot group, blood perfusion returned to or above control within 2 hours, ADC and ATP normalized, tissue pH exhibited alkalosis, and T2 and blood-brain barrier permeability did not change. In the thrombin-induced clot group, in contrast, blood reperfusion was delayed, ADC and ATP remained reduced, tissue pH was acidic, and edema developed, as reflected by increased T2 and blood-brain barrier permeability.

Conclusions--rtPA-induced thrombolysis promotes rapid reperfusion and tissue recovery in animals embolized with spontaneously forming clots but not in those embolized with thrombin-induced clots. This difference is explained by the different mechanical and possibly molecular consequences of clot preparation and must be considered for the interpretation of thrombolysis experiments.


Key words: brain edema • cerebral hemorrhage • stroke, experimental • thrombin • thrombolysis




This article has been cited by other articles:


Home page
StrokeHome page
A. Forster, A. Gass, R. Kern, M. E. Wolf, C. Ottomeyer, K. Zohsel, M. Hennerici, and K. Szabo
Gender Differences in Acute Ischemic Stroke: Etiology, Stroke Patterns and Response to Thrombolysis
Stroke, July 1, 2009; 40(7): 2428 - 2432.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. M. Simard, V. Yurovsky, N. Tsymbalyuk, L. Melnichenko, S. Ivanova, and V. Gerzanich
Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke * Supplemental Methods
Stroke, February 1, 2009; 40(2): 604 - 609.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
T. Saguchi, H. Onoue, M. Urashima, T. Ishibashi, T. Abe, and H. Furuhata
Effective and Safe Conditions of Low-Frequency Transcranial Ultrasonic Thrombolysis for Acute Ischemic Stroke: Neurologic and Histologic Evaluation in a Rat Middle Cerebral Artery Stroke Model
Stroke, March 1, 2008; 39(3): 1007 - 1011.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Orset, R. Macrez, A. R. Young, D. Panthou, E. Angles-Cano, E. Maubert, V. Agin, and D. Vivien
Mouse Model of In Situ Thromboembolic Stroke and Reperfusion
Stroke, October 1, 2007; 38(10): 2771 - 2778.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
I. B. Kovacs and J. Yamamoto
Spontaneous Thrombolysis: A Forgotten Determinant of Life or Death
Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 358 - 363.
[Abstract] [PDF]


Home page
StrokeHome page
S. I. Savitz, G. Schlaug, L. Caplan, and M. Selim
Arterial Occlusive Lesions Recanalize More Frequently in Women Than in Men After Intravenous Tissue Plasminogen Activator Administration for Acute Stroke
Stroke, July 1, 2005; 36(7): 1447 - 1451.
[Abstract] [Full Text] [PDF]